| OVT | Oncolytic virus therapy |
| Ads | Adenoviruses |
| HAdV | Human Adenovirus |
| nAbs | Neutralizing antibodies |
| TME | Tumor microenvironment |
| CAR | Coxsackie and Adenovirus receptor |
| DSG-2 | Desmoglein-2 |
| HSPG | Heparan sulphate proteoglycan |
| VCAM-1 | Vascular cell adhesion molecule-1 |
| MHC-I α2 | Major histocompatibility complex-1 α2 domain |
| MARCO | Macrophage receptor with collagenous structure |
| SA | Sialic acid |
| TJ | Tight junction |
| IRS | Immunoreactive score |
| HIF-1 α | Hypoxia inducible factor-1α |
| EMT | Epithelial to mesenchymal transition |
| STAT3 | Signal transducers and activators of transcription 3 |
| APC | Antigen presenting cell |
| CMP | Cytidine-monophosphate |
| TAM | Tumor associated macrophage |
| FX | Factor X |
| DPPC | Dipalmitoyl phosphatidylcholine |
| HSV | Herpes Simplex Virus |